Stock Report: Navidea Biopharmaceuticals Inc (NAVB) Report Updated: May 20, 2013 | Print This Page

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of precision diagnostics and radiopharmaceutical agents. The company’s radiopharmaceutical development programs include Lymphoseek, a radiopharmaceutical agent for determining the spread of solid tumor cancers into the lymphatic system; AZD4694 intended for use in the imaging and evaluation of patients with signs or symptoms of cognitive impairment, such as Alzheimer’s disease; and RIGScan, a tumor antigen-specific targeting agent intended to help surgeons locate cancerous or disease-involved tissue during colorectal cancer surgeries. It has a biopharmaceutical development and supply agreement with Laureate Biopharmaceutical Services, Inc. to support manufacturing process development work, initial evaluation of the CC49 master working cell bank, and the initial steps in re-validating the clinical grade and commercial production process for a humanized version of the RIGScan antibody. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. on January 05, 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.